TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

被引：26

作者：

Ahn, M. ^{[1
]}

Han, J. ^{[2
]}

Sequist, L. ^{[3
]}

Cho, B. C. ^{[4
]}

Lee, J. S. ^{[5
]}

Kim, S. ^{[6
]}

Su, W. ^{[7
]}

Tsai, C. ^{[8
]}

Yang, J. C. ^{[9
]}

Yu, H. ^{[10
]}

Horn, L. ^{[11
]}

Lee, K. ^{[12
]}

Haddad, V. ^{[13
]}

Frigault, M. ^{[14
]}

Ahmed, G. ^{[13
]}

Yang, L. ^{[15
]}

Ghiorghiu, D. ^{[13
]}

Oxnard, G. ^{[16
]}

机构：

[1] Samsung Med Ctr, Seoul, South Korea

[2] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea

[3] Massachusetts Gen Hosp, Boston, MA 02114 USA

[4] Yonsei Canc Ctr, Med Oncol, Seoul, South Korea

[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan

[9] Natl Taiwan Univ Hosp, Taipei, Taiwan

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[12] Taipei Med Univ, Shuang Ho Hosp, Taipei, Taiwan

[13] Astrazeneca, Cambridge, England

[14] Astrazeneca, Waltham, MA USA

[15] Astrazeneca, Shanghai, Peoples R China

[16] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

non-small cell lung cancer; EGFR-Mutant; MET-amplification;

D O I：

10.1016/j.jtho.2017.09.377

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA 09.03

引用

页码：S1768 / S1768

页数：1

共 50 条

[41] First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Hafner, Susanne
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
[42] First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Susanne Hafner
Signal Transduction and Targeted Therapy, 6
[43] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
Tamura, Tomoki
Hotta, Katsuyuki
Gotoda, Hiroko
Kato, Yuka
Ichihara, Eiki
Kubo, Toshio
Tanimoto, Mltsune
Kiura, Katsuyuki
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[44] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
Smit, E. F.
Felip, E.
Karachaliou, N.
Ellers-Lenz, B.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
[45] Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
Piper-Vallillo, Andrew J.
Halbert, Brian T.
Rangachari, Deepa
Kobayashi, Susumu S.
Costa, Daniel B.
JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
[46] Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation- Positive, MET-Amplified Non-Small Cell Lung Cancer Model
Jones, Rhys D. O.
Petersson, Klas
Tabatabai, Areya
Bao, Larry
Tomkinson, Helen
Schuller, Alwin G.
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (05) : 679 - 690
[47] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
Smit, E.
Felip, E.
Karachaliou, N.
Ellers-Lenz, B.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
[48] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
Wu, Y-L.
Dooms, C.
Nadal, E.
Raskin, J.
Demedts, I.
Mazieres, J.
Wislez, M.
Abdul Shukor, S.
Tho, L. M.
Wang, C-C.
Viteri, S.
Le, X.
How, S. H.
Tan, D.
Takeda, M.
Veillon, R.
Karachaliou, N.
Ellers-Lenz, B.
Smit, E. F. F.
ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
[49] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Kim, T. M.
Guarneri, V.
Jye, V. P.
Khaw, L. B.
Yang, J. -J.
Wislez, M.
Huang, C.
Kin, L. Chong
Mazieres, J.
Tho, L. M.
Hayashi, H.
Nhung, N.
Chia, P. L.
De Marinis, F.
Raskin, J.
Zhou, Q.
Finochhiaro, G.
Le, X.
Tan, D.
Brutlach, S.
O'Brate, A.
Adrian, S.
Berghoff, K.
Ellers-Lenz, B.
Karachaliou, N.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
[50] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
Le, Xiuning
Kim, Tae Min
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Yang, Jinji
Wislez, Marie
Huang, Cheng
Liam, Chong Kim
Mazieres, Julien
Lye Mun Tho
Hayashi, Hidetoshi
Nguyen Nhung
Chia, Puey Ling
De Marinis, Fillippo
Raskin, Jo
Zhou, Qinghua
Finochhiaro, Giovanna
Tan, Daniel
Brutlach, Sabine
O'Brate, Aurora
Adrian, Svenja
Berghoff, Karin
Ellers-Lenz, Barbara
Karachaliou, Niki
Wu, Yi-Long
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)

← 1 2 3 4 5 →